Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00055809
Other study ID # NCI-2012-02519
Secondary ID MDA-ID-02063N01C
Status Completed
Phase Phase 2
First received March 6, 2003
Last updated January 22, 2013
Start date January 2003

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PEG-interferon alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. Combining bevacizumab with PEG-interferon alfa-2b may kill more cancer cells


Description:

OBJECTIVES:

I. Determine the progression-free survival rate in patients with metastatic or unresectable carcinoid tumors treated with bevacizumab and PEG-interferon alfa-2b.

II. Determine the tumor response rate (complete and partial) in patients treated with this regimen.

III. Determine the biochemical response rate of patients treated with this regimen.

IV. Determine the qualitative and quantitative toxicity and reversibility of toxicity of this regimen in these patients.

OUTLINE: This is a randomized study. Patients are treated in 2 stages.

Stage I: Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive bevacizumab IV on day 1.

Arm II: Patients receive PEG-interferon alfa-2b subcutaneously (SC) on days 1, 8, and 15.

In both arms, courses repeat every 3 weeks. Patients with progressive disease at 9 weeks proceed to stage II. All other patients proceed to stage II after 18 weeks on stage I.

Stage II: Patients receive bevacizumab IV on day 1 and PEG-interferon alfa-2b SC once weekly. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) and remain in CR for 2 additional courses come off study. Patients are followed for survival.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date
Est. primary completion date June 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed carcinoid tumor

- Metastatic or unresectable local-regional disease

- Measurable disease

- No osseous metastasis as the only site of disease

- No history or clinical evidence of CNS disease (e.g., primary brain tumor or any brain metastasis)

- Performance status - Zubrod 0-2

- Performance status - Karnofsky 70-100%

- At least 12 weeks

- See Immunologic

- Absolute granulocyte count > 1,500/mm^3

- Platelet count > 100,000/mm^3

- Hemoglobin > 8 g/dL

- No bleeding diathesis or coagulopathy

- No hemoglobinopathies (e.g., thalassemia) or any other cause of hemolytic anemia

- Bilirubin < 1.5 mg/dL

- INR < 1.5 (if receiving warfarin)

- No evidence of decompensated liver disease (e.g., ascites, bleeding varices, or spontaneous encephalopathy)

- Creatinine < 1.5 mg/dL

- No baseline proteinuria

- Patients with proteinuria (= 2+ or = 100 mg/dL on urinalysis) are allowed provided 24-hour urinary protein is < 500 mg

- No New York Heart Association grade II-IV congestive heart failure

- No serious cardiac arrhythmia requiring medication

- No clinically significant peripheral vascular disease

- No history of stroke

- None of the following within the past 6 months:

- Uncontrolled hypertension

- Transient ischemic attack

- Cerebrovascular accident

- Unstable angina

- Myocardial infarction

- No chronic pulmonary disease (e.g., chronic obstructive pulmonary disease)

- No documented pulmonary hypertension

- None of the following immunologically mediated diseases:

- Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)

- Rheumatoid arthritis

- Idiopathic thrombocytopenia purpura

- Systemic lupus erythematosus

- Autoimmune hemolytic anemia

- Scleroderma

- Severe psoriasis

- No serious concurrent infections

- No active infection requiring parental antibiotics on day 0

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies

- No known hypersensitivity to interferon alfa or to any excipient or vehicle included in its formulation or delivery system

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No significant traumatic injury within the past 4 weeks

- No preexisting thyroid abnormality for which thyroid function can not be normalized by medication

- No concurrent nonmalignant uncontrolled medical illness or one whose control may be jeopardized by the complications of this study therapy

- No uncontrolled psychiatric disorder

- No psychiatric disorders that would preclude study compliance

- No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix

- No serious nonhealing wound ulcer or bone fracture

- No seizures not controlled with standard medical therapy

- Prior immunotherapy allowed

- No prior interferon

- No concurrent immunotherapy

- At least 4 weeks since prior chemotherapy, including radiosensitizers

- No more than 1 prior chemotherapy regimen, including radiosensitizers

- No concurrent chemotherapy

- At least 4 weeks since prior radiotherapy

- Prior radiotherapy must not have contained the single evaluable lesion of this study in a radiation field

- No concurrent radiotherapy

- At least 4 weeks since prior major surgery or open biopsy (1 week for minor surgery) and recovered

- No concurrent or recent full-dose anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters)

- No concurrent chronic daily aspirin (more than 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
PEG-interferon alfa-2b
Given SC
bevacizumab
Given IV
Other:
laboratory biomarker analysis
Optional correlative studies

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor response rate (CR + PR) as measured by RECIST criteria Up to 4 years No
Secondary Progression free survival From the time of initial treatment to the time of PD or death, assessed up to 4 years No
Secondary Biochemical response rate measured after treatment Up to 4 years No
Secondary Toxicity graded according to CTC v3.0 criteria for adverse outcomes Up to 4 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05176665 - EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers Phase 1/Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Terminated NCT00084461 - Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Phase 2
Completed NCT01155258 - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1
Completed NCT00131911 - Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Phase 2
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Completed NCT00397384 - Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Phase 1
Completed NCT00655655 - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT00075439 - Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00093782 - Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Phase 2
Completed NCT00031681 - 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Phase 1
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1
Completed NCT02259725 - Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Phase 2